JPS6416721A - Antioxidant - Google Patents

Antioxidant

Info

Publication number
JPS6416721A
JPS6416721A JP16969787A JP16969787A JPS6416721A JP S6416721 A JPS6416721 A JP S6416721A JP 16969787 A JP16969787 A JP 16969787A JP 16969787 A JP16969787 A JP 16969787A JP S6416721 A JPS6416721 A JP S6416721A
Authority
JP
Japan
Prior art keywords
gomisin
drug
give
active ingredient
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP16969787A
Other languages
Japanese (ja)
Inventor
Shizuo Toda
Yukinobu Iketani
Heihachiro Taguchi
Hiroshi Mihashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsumura and Co
Original Assignee
Tsumura and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsumura and Co filed Critical Tsumura and Co
Priority to JP16969787A priority Critical patent/JPS6416721A/en
Publication of JPS6416721A publication Critical patent/JPS6416721A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To obtain an antioxidant effective for preventing aging and arteriosclerosis, containing gomisin N as an active ingredient. CONSTITUTION:Schisandrae Fructus, a crude drug, is dried, extracted, separated and purified to give gomisin N, which is used as an active ingredient and pharmaceutically manufactured as it is or blended with a conventional carrier for preparation and pharmaceutically manufactured by a conventional procedure to give the aimed substance. The substance can be prepared into an oral drug such as tablet, capsule, granule, fine granule or powder or parenteral drug such as injection or suppository. A dose is 20-600mg calculated as weight of gomisin N per adult daily and administered dividedly several times in the case of oral administration and properly 1-60mg calculates as weight of gomisin N per adult daily in the case of parenteral administration.
JP16969787A 1987-07-09 1987-07-09 Antioxidant Pending JPS6416721A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP16969787A JPS6416721A (en) 1987-07-09 1987-07-09 Antioxidant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16969787A JPS6416721A (en) 1987-07-09 1987-07-09 Antioxidant

Publications (1)

Publication Number Publication Date
JPS6416721A true JPS6416721A (en) 1989-01-20

Family

ID=15891209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16969787A Pending JPS6416721A (en) 1987-07-09 1987-07-09 Antioxidant

Country Status (1)

Country Link
JP (1) JPS6416721A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041778A1 (en) * 1999-12-08 2001-06-14 Samyang Genex Corporation Melanin synthesis inhibition compound and composition containing the same
WO2002032417A1 (en) * 2000-10-19 2002-04-25 Elcom Bio Technology, Co., Ltd. Pharmaceutical preparations containing a dibenzocyclooctane lignan derivative for prevention and treatment of neurodegenerative disease
JP2007510000A (en) * 2003-11-07 2007-04-19 コグニス・フランス・ソシエテ・パール・アクシオン・サンプリフィエ Plant extracts and their use in pharmaceuticals and cosmetics
FR2920089A1 (en) * 2007-08-24 2009-02-27 Greentech USE OF 2.2-CYCLOLIGNANES AS PROMOTERS FOR THE PIGMENTATION OF SKIN OR HAIR
US20120052142A1 (en) * 2010-08-26 2012-03-01 Dr. Chang Naturals, LLC BIOLOGICALLY ACTIVE COMPOSITIONS FROM Schisandra chinensis FOR TREATING COLORECTAL CANCER
CN104223297A (en) * 2014-09-05 2014-12-24 青岛恒波仪器有限公司 Aging-delaying health schisandra chinensis oral solution and preparation method thereof
US11043294B2 (en) 2008-11-25 2021-06-22 Fox Factoory, Inc. Methods and apparatus for virtual competition

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041778A1 (en) * 1999-12-08 2001-06-14 Samyang Genex Corporation Melanin synthesis inhibition compound and composition containing the same
WO2002032417A1 (en) * 2000-10-19 2002-04-25 Elcom Bio Technology, Co., Ltd. Pharmaceutical preparations containing a dibenzocyclooctane lignan derivative for prevention and treatment of neurodegenerative disease
KR100380634B1 (en) * 2000-10-19 2003-04-26 주식회사 엘컴사이언스 Composition containing a dibenzocyclooctane lignan derivative for prevention or treatment of neurodegenerative disease
JP2007510000A (en) * 2003-11-07 2007-04-19 コグニス・フランス・ソシエテ・パール・アクシオン・サンプリフィエ Plant extracts and their use in pharmaceuticals and cosmetics
FR2920089A1 (en) * 2007-08-24 2009-02-27 Greentech USE OF 2.2-CYCLOLIGNANES AS PROMOTERS FOR THE PIGMENTATION OF SKIN OR HAIR
WO2009027330A1 (en) * 2007-08-24 2009-03-05 Greentech Use of 2,2'-cyclolignanes for inducing, restoring or stimulating the pigmentation of the skin, hair or hairs
US11043294B2 (en) 2008-11-25 2021-06-22 Fox Factoory, Inc. Methods and apparatus for virtual competition
US20120052142A1 (en) * 2010-08-26 2012-03-01 Dr. Chang Naturals, LLC BIOLOGICALLY ACTIVE COMPOSITIONS FROM Schisandra chinensis FOR TREATING COLORECTAL CANCER
CN104223297A (en) * 2014-09-05 2014-12-24 青岛恒波仪器有限公司 Aging-delaying health schisandra chinensis oral solution and preparation method thereof

Similar Documents

Publication Publication Date Title
GR3026674T3 (en) Dosage form for a delayed drug delivery.
PL318649A1 (en) Preparation to be administered by inhalation
JPS6416721A (en) Antioxidant
EP0629400A1 (en) Idebenone compositions for treating Alzheimer's disease
JPS6452721A (en) Diabetic remedy containing 7-thiapprostaglandin e1 as active ingredient
JPS57106618A (en) Anticancer agent consisting of polyprenyl compound
Acocella et al. Serum and urine concentrations of rifampicin administered by intravenous infusion in man
JPS5793913A (en) Enhancing agent for spermous vital power
US3795736A (en) 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1) benzopyrano(3,4-d)pyridine as an analgesic agent
JPS6466125A (en) Remedy for gastritis
JPS643121A (en) Remedy for endometriosis
US20190381034A1 (en) Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
JPS57114512A (en) Antidia beticagent comprising (3-dimethyl-carbamoxy- phenyl)trimethyl ammonium derivative
Hladovec et al. Oral contraceptives, methionine and endothelial lesion
US3777028A (en) 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-2-(2-propynyl)-1,2,3,4-tetrahydro-5h-(1)-benzopyrano(3,4-d)pyridine as an anti-diarrheal agent
JPS6456615A (en) Remedy for nephropathy
JPS6425728A (en) Nootropic (noesis improving agent)
KR920019356A (en) Pharmaceutical Compositions and Methods of Making the Same
JPS54132239A (en) Anti-tumor agent
DK0483320T3 (en) Prolonged-release pharmaceutical compositions for oral administration and methods for their preparation
JPS6452723A (en) Suppressant against multiplication of aids virus
JPS5462327A (en) Remedy for dna virus infectious disease
JPS6416723A (en) Antithrombotic agent
JPS56133290A (en) Nitrile compound and drug comprising it
JPS57126422A (en) Stabilizing method of lysozyme pharmaceutical